STOKE THERAPEUTICS AND BIOGEN PRESENT LONG-TERM CLINICAL DATA THAT SUPPORT THE DISEASE-MODIFYING POTENTIAL OF ZOREVUNERSEN, AN INVESTIGATIONAL MEDICINE FOR THE TREATMENT OF DRAVET SYNDROME, AT THE 16TH EUROPEAN EPILEPSY CONGRESS (EEC)

Reuters · 2d ago

Please log in to view news